Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
105.40    2.20 (2.13%)
Bid:
105.40
Ask:
105.80
Spread: 0.40 (0.38%)
Market Cap: £172.80m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

7 Nov 2013 07:00

RNS Number : 3806S
Synthomer PLC
07 November 2013
 



7th November 2013

 

SYNTHOMER PLC

 

INTERIM MANAGEMENT STATEMENT

 

Synthomer plc ("Synthomer" or "the Group") today issues its interim management statement for the period 1 July to 6 November 2013.

 

Trading

 

The Group has performed broadly in line with the Board's expectations since the last update provided at the interim results in August.

 

Trading conditions in Europe have remained challenging, particularly in construction related areas, resulting in Europe and North America (ENA) operating profit being slightly below the same period last year. Whilst volumes showed some improvement over the prior year, the softer margins we saw in the first half persisted. In a difficult demand environment, a number of pricing actions have been taken.

 

In Asia and ROW, trading has remained strong. The solid demand for nitrile products seen during the first half of the year continued throughout the period reflecting the ongoing benefits of new product launches at the beginning of the year.

 

The Group's financial position remains robust with net debt at the period end slightly lower than the level reported at the interim results. As we approach the end of the year, we expect the seasonal working capital profile of the business to ease, further improving our net debt position.

 

Outlook

 

In Europe, where we have seen no material improvement in market conditions to date, we continue to expect second half operating profit to be lower than the first half of the year. This will reflect the impact of normal seasonal factors and is expected to deliver ENA profitability slightly below that achieved in the second half of the prior year. The Board continues to expect Asia and ROW operating profit in the second half to be in line with the first half, substantially ahead of the prior year.

 

Commenting Adrian Whitfield, Chief Executive Officer, said:

 

"Whilst challenging market conditions in Europe have persisted, our business has held up well and strong cash generation is enabling us to maintain investment in emerging market growth. The nitrile business in Asia has continued its solid performance and we are encouraged by the demand growth in the region."

 

Enquiries:

 

Adrian Whitfield, Chief Executive Officer

Charles Armitstead / Rosie Oddy

David Blackwood, Chief Financial Officer

Pendomer Communications

Tel: 01279 442791

Tel: 020 3603 5220

 

The company will host a conference call for analysts at 8.30am today. Please contact Pendomer Communications on 020 3603 5220 for dial in details.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUNSSROAAARAA
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.